FirstWave Capital Management LLC boosted its holdings in PROCEPT BioRobotics Corporation (NASDAQ:PRCT – Free Report) by 79.7% during the 2nd quarter, Holdings Channel reports. The fund owned 144,408 shares of the company’s stock after acquiring an additional 64,069 shares during the quarter. PROCEPT BioRobotics comprises 1.4% of FirstWave Capital Management LLC’s portfolio, making the stock its 21st largest holding. FirstWave Capital Management LLC’s holdings in PROCEPT BioRobotics were worth $3,261,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd grew its stake in shares of PROCEPT BioRobotics by 436.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after purchasing an additional 746 shares in the last quarter. Versant Capital Management Inc grew its position in PROCEPT BioRobotics by 994.5% in the 2nd quarter. Versant Capital Management Inc now owns 1,193 shares of the company’s stock valued at $27,000 after buying an additional 1,084 shares in the last quarter. Nykredit A S acquired a new position in PROCEPT BioRobotics during the 2nd quarter valued at about $27,000. Center for Financial Planning Inc. bought a new stake in shares of PROCEPT BioRobotics during the 4th quarter worth about $40,000. Finally, US Bancorp DE raised its position in shares of PROCEPT BioRobotics by 175.7% during the 3rd quarter. US Bancorp DE now owns 1,693 shares of the company’s stock worth $60,000 after buying an additional 1,079 shares in the last quarter. Institutional investors own 89.46% of the company’s stock.
Key PROCEPT BioRobotics News
Here are the key news stories impacting PROCEPT BioRobotics this week:
- Positive Sentiment: The stock’s increase suggests investors may be treating the latest announcements as repetitive legal notices rather than a new deterioration in the company’s business. The reports did not announce a judgment, settlement, regulatory penalty, or additional financial charge.
- Neutral Sentiment: Multiple firms—including Kaplan Fox class action deadline Kaplan Fox, Hagens Berman investor deadline Hagens Berman, and Rosen Law investor deadline Rosen Law—reminded investors that September 22, 2026 is the deadline to seek lead-plaintiff status. The proposed class covers purchases made from February 28, 2024, through February 25, 2026.
- Negative Sentiment: The lawsuit alleges that PROCEPT made misleading statements or failed to disclose repeated weakness in unit handpiece sales and excess customer inventory, allegedly caused in part by late-quarter bulk discounts. Law firms say these issues contributed to a substantial stock decline, including an approximately 18% drop cited in the filings. The allegations remain unproven, but continued litigation could increase costs, management distraction, and investor uncertainty. Hagens Berman securities fraud lawsuit
PROCEPT BioRobotics Stock Up 6.5%
PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The company had revenue of $94.50 million during the quarter, compared to the consensus estimate of $92.77 million. During the same period in the prior year, the company posted ($0.35) EPS. PROCEPT BioRobotics’s quarterly revenue was up 19.3% on a year-over-year basis. Equities research analysts forecast that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on PRCT shares. William Blair cut shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Citigroup downgraded PROCEPT BioRobotics to a “hold” rating in a research report on Thursday, July 2nd. Robert W. Baird set a $20.00 price target on PROCEPT BioRobotics in a research note on Wednesday, August 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research note on Friday, July 17th. Finally, Wells Fargo & Company lowered PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 price objective for the company. in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $25.09.
Read Our Latest Report on PROCEPT BioRobotics
Insider Activity
In related news, CEO Larry Wood bought 23,900 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were bought at an average cost of $20.85 per share, with a total value of $498,315.00. Following the completion of the transaction, the chief executive officer directly owned 23,900 shares of the company’s stock, valued at approximately $498,315. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders sold 1,000 shares of company stock valued at $28,480. Insiders own 4.00% of the company’s stock.
PROCEPT BioRobotics Profile
PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.
The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.
Featured Stories
- Five stocks we like better than PROCEPT BioRobotics
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Want to see what other hedge funds are holding PRCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PROCEPT BioRobotics Corporation (NASDAQ:PRCT – Free Report).
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.
